Lifeline Biotechnologies Continues FDA Filing Preparation Process for the First Warning System™

Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) announced today that it has retained a new FDA consulting company to assist in the preparation and filing of its First Warning System™ 510(k) application.

Jim Holmes, Lifeline’s CEO, said, “The work by the prior FDA consulting firm was partially but not fully completed. The process has caused delays and we have engaged a new firm to assist in the review of our data. There will be a determination as to the adequacy and completeness of our data given the ever-changing FDA requirements. The process is expected to lead to the preparation and filing of our 510(k). We expect to know soon the extent of any additional information this new firm may require in order to complete the 510(k) preparation and submission.”

Holmes continued, “Our efforts continue to attempt to re-establish DTC’s services regarding the trading of Lifeline’s shares.”

Lifeline’s website (www.lbti.com) has been comprehensively updated, providing extensive information on the company, its history and current affairs.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

Lifeline Biotech (CE) (USOTC:LLBO)
Historical Stock Chart
From Oct 2024 to Nov 2024